Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Palatin Technologies, Inc. Common Stock (NY: PTN )

1.000 -0.060 (-5.66%)
Official Closing Price Updated: 8:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 775,653
Open 1.040
Bid (Size) 0.9800 (3)
Ask (Size) 1.020 (10)
Prev. Close 1.060
Today's Range 0.9883 - 1.070
52wk Range 0.6800 - 3.993
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Earnings Scheduled For November 14, 2024
Via Benzinga
Earnings Scheduled For February 13, 2025
Via Benzinga

Performance

YTD
-23.08%
-23.08%
1 Month
-7.41%
-7.41%
3 Month
+5.26%
+5.26%
6 Month
-29.58%
-29.58%
1 Year
-66.89%
-66.89%

More News

Read More
On Friday, there are stocks with unusual volume. Let's take a look.
Via Chartmill
Thursday's session: top gainers and losers
Via Chartmill
Get insights into the top gainers and losers of Monday's after-hours session.
Via Chartmill
A Look Ahead: Palatin Techs's Earnings Forecast
Via Benzinga
Earnings Scheduled For February 15, 2024
Via Benzinga
Earnings Preview: Palatin Techs
Via Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions
Via News Direct
Exposures Product Safety
PTN Stock Earnings: Palatin Techs Misses EPS for Q3 2024
Via InvestorPlace
Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Palatin Technologies' Disappointing Data From Dry Eye Disease Study, Stock Plummets
Via Benzinga
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Dow Dips 200 Points; TJX Posts Upbeat Sales
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
The 3 Best Penny Stocks to Buy in February 2024
Via InvestorPlace
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
Via InvestorPlace
3 Penny Stocks to Buy to Unlock 2,500% Upside Potential
Via InvestorPlace
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.